Public, NASDAQ:IDRA
NASDAQ Global Market
Idera Pharmaceuticals Forms Autoimmune Disease Scientific Advisory Board
Date: Mon, 16 Jun 2008 12:39:30 GMT
Tags:
Idera Pharmaceuticals Forms Autoimmune Disease Scientific Advisory Board
Centre Daily Times - Jun 16, 2008
Centre Daily Times - Jun 16, 2008
CAMBRIDGE , Mass . - Idera Pharmaceuticals ( Nasdaq : IDRA ) , a biopharmaceutical company focused on developing therapeutics targeting Toll - Like Receptors ( TLRs ) , today announced the formation ...
Idera Pharmaceuticals Forms Autoimmune Disease Scientific Advisory Board
Date: Mon, 16 Jun 2008 12:14:53 GMT
Tags:
Idera Pharmaceuticals Forms Autoimmune Disease Scientific Advisory Board
Business Wire (press release) - Jun 16, 2008
Business Wire (press release) - Jun 16, 2008
CAMBRIDGE , Mass . - - ( BUSINESS WIRE ) - - Idera Pharmaceuticals ( Nasdaq : IDRA ) , a biopharmaceutical company focused on developing therapeutics targeting Toll - Like Receptors ( TLRs ) ...
Stock Profiler.US: Healthcare Stock News: TEVA, GB, LH, HSIC, GRMH, IDRA
Date: Fri, 13 Jun 2008 15:23:49 GMT
Tags:
Stock Profiler.US: Healthcare Stock News: TEVA, GB, LH, HSIC, GRMH, IDRA
Trading Markets (press release) - Jun 13, 2008
Trading Markets (press release) - Jun 13, 2008
New York , NY , Jun 13 , 2008 ( M2 PRESSWIRE via COMTEX ) - - GB | Quote | Chart | News | PowerRating - - Teva Pharmaceutical Industries Ltd . ( NASDAQ : TEVA ) ; Greatbatch , Inc . ( NYSE : ...
Idera Pharmaceuticals to Present at BIO Business Forum 2008
Date: Fri, 13 Jun 2008 13:54:17 GMT
Tags:
Idera Pharmaceuticals to Present at BIO Business Forum 2008
FOXBusiness - Jun 13, 2008
FOXBusiness - Jun 13, 2008
CAMBRIDGE , Mass . , Jun 13 , 2008 ( BUSINESS WIRE ) - - - - Idera Pharmaceuticals , Inc . ( Nasdaq : IDRA ) , a biopharmaceutical company focused on developing therapeutics targeting Toll - ...
Idera Pharma announces preclinical results of TLR antagonist candidates
Date: Mon, 09 Jun 2008 18:22:08 GMT
Tags:
Idera Pharma announces preclinical results of TLR antagonist candidates
RTT News - Jun 9, 2008
RTT News - Jun 9, 2008
( RTTNews ) - Idera Pharmaceuticals , Inc . ( IDRA : News , Chart , Quote ) , a biotechnology company , announced on Monday preclinical results from novel Toll - like Receptor , or TLR , antagonist ...
Idera Pharma's says TLR antagonist may have potential in treatment of lung inflammatory diseases - Quick Facts - RTT NewsRussell 2000 adds 53 health care companies (AP)
Date: Mon, 30 Jun 2008 18:16:09 Etc/GMT
Tags:
More than 50 companies in the health care sector were added to the Russell 2000 in this year's reconstitution of the small stock index, while 30 companies in the sector were removed from the index.
Idera Pharmaceuticals Forms Autoimmune Disease Scientific Advisory Board (Business Wire)
Date: Mon, 16 Jun 2008 12:00:00 Etc/GMT
Tags:
CAMBRIDGE, Mass.----Idera Pharmaceuticals , a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors , today announced the formation of an Autoimmune Disease Scientific Advisory Board.
Idera Pharmaceuticals to Present at BIO Business Forum 2008 (Business Wire)
Date: Fri, 13 Jun 2008 12:50:00 Etc/GMT
Tags:
CAMBRIDGE, Mass.----Idera Pharmaceuticals, Inc. , a biopharmaceutical company focused on developing therapeutics targeting Toll-Like Receptors , today announced that it will present at the 2008 BIO International Convention taking place June 17-20, 2008 in San Diego, CA.
IDERA PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and (EDGAR Online)
Date: Tue, 10 Jun 2008 20:56:17 Etc/GMT
Tags:
Idera Pharmaceuticals Presents Preclinical Data of Toll-Like Receptor Antagonists in Models of Lung Inflammation and Psoriasis (Business Wire)
Date: Mon, 9 Jun 2008 12:00:00 Etc/GMT
Tags:
CAMBRIDGE, Mass.----Idera Pharmaceuticals, Inc. today announced that presentations from studies evaluating its novel Toll-like Receptor antagonist candidates in preclinical models of lung inflammation and psoriasis were made at the Federation of Clinical Immunology Societies 2008 Annual Meeting held in Boston, MA, June 5-9.